Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL613124 Target Snapshot

Human gammaherpesvirus 4 · ORGANISM · Human gammaherpesvirus 4

Back to Search Search this target Browse approvals Evidence Card
617Compounds
143Assays
8Approved Drugs
488.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human gammaherpesvirus 4 as ChEMBL target CHEMBL613124. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Human gammaherpesvirus 4
ORGANISM · Human gammaherpesvirus 4
As of 2026-09-14
ChEMBL target ID
CHEMBL613124
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Human gammaherpesvirus 4 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameHuman gammaherpesvirus 4
Target TypeORGANISM
OrganismHuman gammaherpesvirus 4
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHuman gammaherpesvirus 4
UniProt AccessionN/A

Human gammaherpesvirus 4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Human gammaherpesvirus 4.

Review nameHuman gammaherpesvirus 4
OrganismHuman gammaherpesvirus 4
Clinical Profile

Clinical Phase Distribution

8
Approved
1
Phase III
4
Phase II
Assay Mix

Activity Type Distribution

IC50129.0
EC50359.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL225981 8.21 IC50 6.1 Preclinical
CHEMBL225870 8.19 IC50 6.4 Preclinical
CHEMBL224808 8.17 IC50 6.7 Preclinical
CHEMBL225923 8.17 IC50 6.7 Preclinical
CHEMBL376789 8.17 IC50 6.7 Preclinical
CHEMBL225922 8.14 IC50 7.3 Preclinical
CHEMBL425302 8.13 IC50 7.4 Preclinical
CHEMBL225869 8.09 IC50 8.1 Preclinical
CHEMBL226136 8.07 IC50 8.6 Preclinical
CHEMBL226137 8.07 IC50 8.6 Preclinical
Distribution

pChEMBL Value Distribution

58
5.0
40
5.5
22
6.0
20
6.5
7
7.0
10
7.5
41
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CIDOFOVIR
CHEMBL5314375
Approved 1996
Properties Compare Identifier
LAMIVUDINE
CHEMBL141
Approved 1995
Properties Compare Identifier
GANCICLOVIR
CHEMBL182
Approved 1989
Properties Compare Identifier
BETA CAROTENE
CHEMBL1293
Approved 1982
Properties Compare Identifier
ACYCLOVIR
CHEMBL184
Approved 1982
Properties Compare Identifier
TRETINOIN
CHEMBL38
Approved 1971
Properties Compare Identifier
Assay Landscape

Assay Landscape

143
Total Assays
255
Tested Compounds
2
Assay Types
Functional — 141 assays, 255 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 140 243 5.8
cell-based format 1 12 5.5
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine